A new play­er is tak­ing the field in a push for a he­mo­phil­ia A gene ther­a­py, and it’s a big one

Bio­Marin, the ex­ecs at Spark (and buy­er-to-be Roche) as well as the Sang­amo/Pfiz­er team have a new ri­val strid­ing on­to the he­mo­phil­ia block. And it’s a big one.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER